-Supplying 'WINUF Central 736·1085ml' through Mongolian pharmaceutical company AsiaPharma LLC
-First WINUF export in the Asia region, with expectations of expanding exports to other countries
November 2023
JW Holdings has announced that it will officially start exporting the Total Parenteral Nutrition 'WINUF Central 736·1085ml' (hereafter, WINUF) to AsiaPharma LLC in Mongolia.
JW Holdings, responsible for JW Group's global business, signed an exclusive supply agreement for WINUF in the Mongolian market with AsiaPharma LLC in December 2021.
AsiaPharma LLC is a top local pharmaceutical company in Mongolia established in 2001 with extensive experience for 21 years and specialized in distributing parenteral nutrient solutions. AsiaPharma LLC received product approval for WINUF from the Mongolian Ministry of Health in December last year and officially entered local sales starting this month.
WINUF is a total parenteral nutrition developed by JW Life Science. It separates one container into three chambers to easily mix essential nutrients, including four types of lipids, amino acids, glucose, and fish oil. It is characterized by its high content of Omega-3 and Omega-6, which promote immune system enhancement and recovery more effectively than single nutrient solutions.
In the domestic market, JW Pharmaceutical is responsible for its sales. Since its release in 2013, it has maintained the top position in the total parenteral nutrient solution market.
This is the first time that JW Holdings is exporting WINUF to the Asian market. With the export of WINUF to Mongolia, the company expects to gain momentum for exports to other Asian countries.
A representative of JW Holdings stated, "JW's product development and production competitiveness for high-value total parenteral nutrient solutions have been recognized in the global market." They added, "Now that WINUF has taken its first step into Asian countries, we will further strengthen our position as a global nutrition company by expanding to more countries."
Meanwhile, JW Life Science, an affiliate of JW Holdings, completed the expansion of the automated production facility 'TPN 3 Chamber' for domestic exclusive-volume total parenteral nutrient solutions in its production facility located in Dangjin, Chungcheongnam-do in October last year. With the full operation of 'TPN 3 Line,' the annual maximum production capacity of JW Life Science's total parenteral nutrient solutions has increased by 37% from the previous 10.2 million units to 14 million units. The annual maximum production capacity for all intravenous solutions, including total parenteral nutrient solutions, has become the largest in South Korea, totaling 180 million units.